Diametric Capital LP Acquires Shares of 4,444 Sanofi (NASDAQ:SNY)

Diametric Capital LP bought a new position in Sanofi (NASDAQ:SNY) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 4,444 shares of the company’s stock, valued at approximately $214,000.

A number of other hedge funds also recently made changes to their positions in the company. Raymond James Financial Inc. bought a new stake in Sanofi in the 4th quarter worth approximately $135,933,000. Boston Partners increased its position in Sanofi by 86.4% in the fourth quarter. Boston Partners now owns 5,396,531 shares of the company’s stock worth $260,607,000 after purchasing an additional 2,501,073 shares during the last quarter. Magnetar Financial LLC raised its stake in Sanofi by 104.3% during the fourth quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company’s stock valued at $161,103,000 after purchasing an additional 1,705,148 shares in the last quarter. DAVENPORT & Co LLC lifted its position in Sanofi by 40.7% during the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock valued at $110,715,000 after purchasing an additional 664,455 shares during the last quarter. Finally, Thrivent Financial for Lutherans grew its stake in shares of Sanofi by 36.0% in the 4th quarter. Thrivent Financial for Lutherans now owns 1,943,761 shares of the company’s stock worth $93,774,000 after buying an additional 514,542 shares in the last quarter. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. The Goldman Sachs Group began coverage on Sanofi in a report on Friday, March 21st. They set a “neutral” rating and a $65.00 price target on the stock. Finally, Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Three research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $62.50.

Sanofi Trading Down 0.7 %

Shares of NASDAQ SNY opened at $53.95 on Thursday. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $60.12. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The company has a market cap of $136.92 billion, a price-to-earnings ratio of 21.67, a PEG ratio of 1.01 and a beta of 0.58. The business’s 50 day moving average price is $55.33 and its 200-day moving average price is $52.74.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, sell-side analysts expect that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.